Homoharringtonine

DRUG17 trials

Sponsors

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), ChemGenex Pharmaceuticals, Ascentage Pharma Group Inc., Ge Zheng

Conditions

AMLAML, ChildhoodAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute T Lymphpblastic Leukemia/LymphomaBlast PhaseChildhood Leukemia, Acute Lymphoblastic

Phase 1

Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

WithdrawnNCT00030355

National Cancer Institute (NCI)Leukemia

Updated: 2013-03-22

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet recruitingNCT07159906

First Affiliated Hospital of Zhejiang UniversityDiffuse Large B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma

Start: 2025-09-08End: 2028-08-01Target: 62Updated: 2025-09-08

Phase 2

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

TerminatedNCT00114959

ChemGenex PharmaceuticalsBlast Phase, Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase +1

Start: 2005-10-31End: 2009-03-31Updated: 2015-01-15

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

CompletedNCT04126681

Ascentage Pharma Group Inc.Chronic Myeloid Leukemia, Chronic Phase

Start: 2019-10-21End: 2024-08-01Updated: 2025-03-03

Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

Ge ZhengAcute Myeloid Leukemia

Start: 2019-12-01End: 2022-12-30Target: 100Updated: 2022-09-08

Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

RecruitingNCT05805098

The First Affiliated Hospital of Soochow UniversityAcute Myeloid Leukemia

Start: 2023-03-01End: 2028-03-01Target: 60Updated: 2023-04-07

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

RecruitingNCT06221683

Children's Hospital of Soochow UniversityAcute Myeloid Leukemia, AML, Childhood

Start: 2024-01-01End: 2029-12-31Target: 500Updated: 2024-08-22

VHAG in Treating R/R T-ALL/LBL

RecruitingNCT06742463

First Affiliated Hospital of Zhejiang UniversityAcute T Lymphpblastic Leukemia/Lymphoma

Start: 2024-12-31End: 2028-06-30Target: 50Updated: 2024-12-19

HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

RecruitingNCT06744556

Institute of Hematology & Blood Diseases Hospital, ChinaAML

Start: 2025-01-21End: 2027-06-01Target: 60Updated: 2025-05-30

Newly-diagnosed Pediatric T-cell ALL Protocol

RecruitingNCT06855810

Institute of Hematology & Blood Diseases Hospital, ChinaAcute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Start: 2025-03-11End: 2031-06-30Target: 610Updated: 2025-08-26

Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study

RecruitingNCT07163910

baotai LiangProstate Cancer

Start: 2025-04-20End: 2027-12-20Target: 93Updated: 2025-11-18

Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients

Not yet recruitingNCT07505160

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAcute Myeloid Leukemia (AML)

Start: 2026-03-01End: 2029-03-01Target: 35Updated: 2026-04-01

Phase 3

Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

TerminatedNCT00004933

Alliance for Clinical Trials in OncologyLeukemia

Start: 2000-01-31End: 2001-05-31Updated: 2016-07-04

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

RecruitingNCT05726110

Shanxi Bethune HospitalRelapsed or Refractory Acute Myeloid Leukemia

Start: 2023-01-29End: 2024-12-31Target: 50Updated: 2024-10-22

Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

RecruitingNCT06361329

First Affiliated Hospital of Zhejiang UniversityETP-ALL

Start: 2024-04-03End: 2027-03-31Target: 81Updated: 2025-02-17

VAH vs VA in Newly Diagnosed Elderly AML

Not yet recruitingNCT07469046

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineAcute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)

Start: 2026-03-01End: 2029-03-31Target: 308Updated: 2026-03-13

Unknown Phase

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

The First Affiliated Hospital of Soochow UniversityRelapsed/Refractory AML

Start: 2023-05-01End: 2024-06-30Target: 20Updated: 2023-05-06

Related Papers

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations

Blood2025-11-03

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Blood2023-11-0210 citations

High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial

Frontiers in Oncology2022-12-085 citations

High Efficacy of Azacitidine Plus Hag in Acute Myeloid Leukemia: A Multi-Center, Phase 2 Clinical Trial

Blood2022-11-15

Azacitidine Combined with Homoharringtonine, Idarubicin/Daunorubicin, Cytarabine for Previously Untreated Patients with Acute Myeloid Leukemia: A Single-Center, Phase 2 Study

Blood2022-11-15

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Journal of Hematology & Oncology2022-08-1889 citations